A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal.
The strategy is described in a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. If verified in an ongoing clinical trial, it could potentially help save the lives of thousands of women each year in the United States alone.
There currently are no established screening strategies for ovarian cancer. The disease often causes no specific symptoms and is difficult to detect in the early stages when it is most responsive to treatment. Therefore, ovarian cancer is highly lethal because most women have advanced disease when they are diagnosed.
Karen Lu, MD, of The University of Texas MD Anderson Cancer Center in Houston, led a team that tested the potential of a two-stage ovarian cancer screening strategy that incorporates changes in a blood protein called CA125, which is a known tumor marker. In their 11-year study, 4051 post- menopausal women initially underwent an annual CA125 blood test. Based on a calculation called the “Risk of Ovarian Cancer Algorithm,” women were divided into three groups: those who should receive another CA125 test one year later (low risk), those who should receive a repeat CA125 in three months (intermediate risk), and those who should receive a transvaginal ultrasound and be referred to a gynecologic oncologist (high risk).
An average of 5.8 percent of women were found to be of intermediate risk each year, meaning that they should receive a CA125 test in three months. The average annual referral rate to transvaginal ultrasound and review by a gynecologic oncologist was 0.9 percent. Ten women underwent surgery based on their ultrasound exams, with four having invasive ovarian cancers, two having ovarian tumors of low malignant potential, one having endometrial cancer, and three having benign ovarian tumors. This equates to a positive predictive value of 40 percent for detecting invasive ovarian cancer. The specificity of the testing strategy was 99.9 percent, meaning that only 0.1 percent of patients without cancer would be falsely identified as having the disease. Importantly, all of the ovarian cancers were early stage.
The Latest on: Ovarian cancer
VIDEO: Niraparib data for ovarian, breast cancers highlight Tesaro presentations at ASCO
on June 20, 2018 at 1:19 pm
Research presented at ASCO explored use of the PARP inhibitor niraparib (MK-4827, Tesaro) in combination with the anti-PD-1 agent pembrolizumab (Keytruda, Merck) for patients with triple-negative breast cancer or platinum-resistant ovarian cancer. […]
VIDEO: Immunotherapy combination demonstrates efficacy in advanced ovarian cancer
on June 20, 2018 at 6:04 am
CHICAGO — Frederic Ors, BSc, CEO of IMV — a clinical stage immuno-oncology corporation — spoke with HemOnc Today about key data the company presented at ASCO Annual Meeting. An oral presentation included positive data from the DeCidE1 study, which ... […]
Ovarian Cancer Drugs Market - Growth, Trends and Demands Research Report and Forecast 2024
on June 19, 2018 at 7:14 pm
Ovarian cancer drugs market supported by growing aging population in the U.S and U.K An alarming rise in number of ovarian cancer cases reported in the recent past, inadvertently creates a highly conducive environment for growth of the ovarian cancer drugs ... […]
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
on June 19, 2018 at 6:41 am
ImmunoGen, Inc. (IMGN - Free Report) announced that the FDA has granted Fast Track designation to its lead candidate, mirvetuximab soravtansine, a first-in-class antibody drug conjugate targeting folate-receptor (“FR”) alpha. The designation is for the ... […]
Ovarian cancer cells switched off by 'unusual' mechanism
on June 19, 2018 at 4:12 am
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells. The findings, published in EMBO Reports, could lead to better treatments for women with ovarian cancer. […]
Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022
on June 18, 2018 at 7:31 am
LONDON, June 18, 2018 /PRNewswire/ -- Report Scope: This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing ... […]
My stomach pain proved to be advanced ovarian cancer, and I didn’t like the odds.
on June 17, 2018 at 6:00 am
I’m glad I was lying down when the doctor told me the true cause of my stomach pains. “Well, you’ve got a tumor” were his first words to me. I had just awakened in a hospital bed on the morning after emergency surgery. It was Tuesday, Oct. 31, 2017. […]
FDA Approvals in Cervical Cancer, Ovarian Cancer, and CLL, and More
on June 15, 2018 at 6:35 am
FDA approvals in cervical cancer, ovarian cancer, and chronic lymphocytic leukemia, a priority review designation in breast cancer, a European approval in non–small cell lung cancer, and a label update in multiple myeloma. Welcome to OncLive News Network! […]
What are the first symptoms of ovarian cancer?
on June 15, 2018 at 5:07 am
It is often difficult to diagnose ovarian cancer in its early stages because the symptoms are similar to those of other conditions. Anyone who experiences unexplained abdominal symptoms that last for more than 2 weeks should see a doctor. Ovarian cancer ... […]
Why ovarian cancer is hard to detect
on June 13, 2018 at 7:51 pm
Ovarian cancer is estimated to affect more than 22,000 women each year and is the fifth leading cause of cancer deaths among women, according to American Cancer Society. Unlike other gynecologic cancers, there are no screening tests for ovarian cancer. […]
via Google News and Bing News